Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'.

Petersenn, Stephan; Fleseriu, Maria; Melmed, Shlomo

Petersenn, Stephan; Fleseriu, Maria; Melmed, Shlomo.

Affiliation

Petersenn S; ENDOC Center for Endocrine Tumors, Hamburg, Germany. stephan.petersenn@endoc-med.de.
Fleseriu M; University of Duisburg-Essen, Essen, Germany. stephan.petersenn@endoc-med.de.
Melmed S; Oregon Health Sciences University, Portland, OR, USA.

Nat Rev Endocrinol ; 20(5): 315, 2024 May.

Article in En | MEDLINE | ID: mdl-38509200

Subject(s)

Pituitary Neoplasms; Prolactinoma; Humans; Prolactinoma/drug therapy; Prolactinoma/pathology; Dopamine Agonists/adverse effects; Pituitary Neoplasms/drug therapy; Pituitary Neoplasms/pathology; Fibrosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pituitary Neoplasms / Prolactinoma Limits: Humans Language: En Journal: Nat Rev Endocrinol Journal subject: ENDOCRINOLOGIA Year: 2024 Document type: Article Affiliation country: Germany Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google